Información:
Error:
ID
12992
Descripción
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder; ODM derived from: https://clinicaltrials.gov/show/NCT00001381
Link
https://clinicaltrials.gov/show/NCT00001381
Palabras clave
Versiones (1)
- 10/1/16 10/1/16 -
Subido en
10 de enero de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Bladder Neoplasms NCT00001381
Eligibility Bladder Neoplasms NCT00001381
- StudyEvent: Eligibility
Similar models
Eligibility Bladder Neoplasms NCT00001381
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Transitional cell carcinoma of the bladder, tumor stage
Item
histologically confirmed superficial transitional cell carcinoma of the bladder pathologically staged as tis, ta, or t1. visible tumors at time of treatment not required. no metastatic disease or muscle invasion.
boolean
C0279680 (UMLS CUI [1])
C1300072 (UMLS CUI [2])
C1300072 (UMLS CUI [2])
Pretreatment, bladder function
Item
clinically useful pretreatment bladder function required.
boolean
C3539076 (UMLS CUI [1])
C0232840 (UMLS CUI [2])
C0232840 (UMLS CUI [2])
prostatic obstructive symptoms, bladder emptying
Item
no significant prostatic obstructive symptoms associated with impaired or incomplete bladder emptying.
boolean
C0268889 (UMLS CUI [1])
C0429805 (UMLS CUI [2])
C0429805 (UMLS CUI [2])
urinary tract infection
Item
no active urinary tract infection.
boolean
C0042029 (UMLS CUI [1])
intravesical therapy
Item
at least 1 course of prior standard intravesical therapy required.
boolean
C0444473 (UMLS CUI [1])
time since intravesical treatment, toxicities
Item
at least 4 weeks since intravesical treatment, with resolution of any local or systemic toxicity.
boolean
C0444473 (UMLS CUI [1])
C0013221 (UMLS CUI [2])
C0013221 (UMLS CUI [2])
age
Item
age: 18 and over.
boolean
C0001779 (UMLS CUI [1])
ecog
Item
performance status: ecog 0 or 1.
boolean
C1520224 (UMLS CUI [1])
wbc
Item
wbc at least 3,300;
boolean
C0023508 (UMLS CUI [1])
hemoglobin
Item
hemoglobin at least 10 g/dl.
boolean
C0019046 (UMLS CUI [1])
bilirubin
Item
bilirubin no greater than 1.5 mg/dl;
boolean
C1278039 (UMLS CUI [1])
ast and alt
Item
ast and alt no greater than 2 times normal.
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201899 (UMLS CUI [2])
creatinine
Item
renal: creatinine no greater than 1.5 mg/dl.
boolean
C0201976 (UMLS CUI [1])
cystoscopy
Item
medically able to undergo cystoscopy.
boolean
C0010702 (UMLS CUI [1,1])
C0085732 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,2])
pregnancy
Item
no pregnant women.
boolean
C0032961 (UMLS CUI [1])